Twelve years experience with etanercept in the treatment of rheumatoid arthritis: How it has changed clinical practice

Expert Review of Clinical Immunology

Volumn 8, Issue 3, 2012, Pages 213-222

  Atzeni, Fabiola ^a,b   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

adverse events; clinical efficacy; etanercept; pharmacokinetics; safety; trials

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ANAPHYLAXIS; APLASTIC ANEMIA; BACTERIAL INFECTION; BONE RADIOGRAPHY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATOBILIARY DISEASE; HUMAN; LISTERIOSIS; LUPUS LIKE SYNDROME; LYMPHOMA; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; MYCOSIS; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SKIN CANCER; SURVIVAL; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VIRUS REACTIVATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DRUG SYNERGISM; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; INFECTION; LYMPHOMA; METHOTREXATE; PHYSICIAN'S PRACTICE PATTERNS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858409214     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.6     Document Type: Review

References (80)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 358, 903-911 (2001).
2. Emery P. Early arthritis. In:Targeted Therapies in Rheumatology Smolen JS, Lipsky PE (Eds). Martin Dunitz, London, UK, 509-513 (2003).
3. van Dongen H, van Aken J, Lard LR et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 56, 1424-1432 (2007).
4. Kirwan JR. Arthritis and rheumatism council low-dose glucocorticoid study group: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N. Engl. J. Med. 333, 142-114 (1995).
5. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 43, 906-914 (2004).
6. van der Heijde D. Radiographic progression in rheumatoid arthritis: Does it reflect outcome? Does it reflect treatment? Ann. Rheum. Dis. 60 (Suppl. 3), iii47-iii50 (2001).
7. Zink A, Strangfeld A, Schneider M et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 54, 3399-3407 (2006).
8. Caporali R, Pallavicini FB, Filippini M et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. Autoimmun. Rev. 8, 274-280 (2009).
9. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907-916 (2001).
10. Wiens GD, Glenney GW. Origin and evolution of TNF and TNF receptor superfamilies. Dev. Comp. Immunol. 35(12), 1324-1335 (2011).
11. Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K. RAPID3 (Routine assessment of patient index data 3) severity categories and response criteria: Similar results to DAS28 (disease activity score) and CDAI (clinical disease activity index) in the RAPID 1 (rheumatoid arthritis prevention of structural damage) clinical trial of certolizumab pegol. Arthritis Care Res. 63(8), 1142-1149 (2011).
12. Ash Z, Emery P. Golimumab - A new tool in the armoury against inflammatory arthritis. Ann. Med. 43(2), 133-141 (2011).
13. Daudén E. Chemical structure of etanercept, pharmacokinetics and mechanism of action. Actas Dermosifiliogr. 101(Suppl. 1), 1-4 (2010).
14. Combe B. Update on the use of etanercept across a spectrum of rheumatoid disorders. Biologics 2, 165-173 (2008).
15. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther. 117(2), 244-279 (2008).
16. Zhou H. Clinical pharmacokinetics of etanercept: A fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J. Clin. Pharmacol. 45, 490-497 (2005).
17. Nestorov I. Clinical pharmacokinetics of TNF antagonists: How do they differ? Semin Arthritis Rheum. 34, 12-18 (2005).
18. Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J. Rheumatol. 74(Suppl.), 13-18 (2005).
19. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93, 2645-2668 (2004).
20. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253-259 (1999).
21. van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. TEMPO study investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54, 1063-1074 (2004).
22. Keystone E, Freundlich B, Schiff M, Li J, Hooper M. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. J. Rheumatol. 36(3), 522-531 (2009).
23. van Riel PL, Taggart AJ, Sany J et al. Add Enbrel or Replace Methotrexate Study Investigators. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. Ann. Rheum. Dis. 65(11), 1478-1483 (2006).
24. Kameda H, Kanbe K, Sato E et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J. Rheumatol. 38, 1585-1592 (2011).
25. Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30(4), 339-353 (2010).
26. Hyrich KL, Symmons DP, Watson KD, Silman AJ; British Society for Rheumatology Biologics Register. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 54, 1786-1794 (2006).
27. Listing J, Strangfeld A, Rau R et al. Clinical and functional remission: Even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res. Ther. 8(3), R66 (2006).
28. Arenere Mendoza M, Manero Ruiz FJ, Carrera Lasfuentes P, Navarro Aznarez H, Pecondon Espanol A, Rabanaque Hernandez MJ. Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: Effectiveness comparative study. Med. Clin. 134, 665-670 (2010).
29. Jin J, Chang Y, Wei W. Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis. Acta Pharmacol. Sin. 31(9), 1133-1140 (2010).
30. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586-1593 (2000).
31. Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum. 46, 1443-1450 (2002).
32. Genovese MC, Bathon JM, Fleischmann RM et al. Long-term safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J. Rheumatol. 32, 1232-1242 (2005).
33. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet 372, 375-382 (2008).
34. Kekow J, Moots RJ, Emery P et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial. Ann. Rheum. Dis. 69, 222-225 (2010).
35. Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford) 50, 401-409 (2011).
36. Koyama Y, Shiraishi H, Ohta T, Uchino A. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate. Mod. Rheumatol. doi:10.1007/s10165-011-0478-8 (2011) (Epub ahead of print).
37. Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi-Puttini P, Atzeni F. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Int. J. Immunopathol. Pharmacol. 24(1), 269-274 (2011).
38. Hetland ML, Christensen IJ, Tarp U et al. All departments of rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 62(1), 22-32 (2010).
39. Marchesoni A, Zaccara E, Gorla R et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann. NY Acad. Sci. 1173, 837-846 (2009).
40. Geborek P, Crnkic M, Petersson IF, Saxne T; South Swedish Arthritis Treatment Group. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann. Rheum. Dis. 61(9), 793-798 (2002).
41. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J. Etanercept study 301 investigators. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 29, 238-247 (2011).
42. Moots RJ, Haraoui B, Matucci-Cerinic M et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: Evidence from clinical practice. Clin. Exp. Rheumatol 29, 26-34 (2011).
43. Thalayasingam N, Isaacs JD. Anti-TNF Therapy. Best Pract. Res. Clin. Rheumatol. 25, 549-567 (2011).
44. Dixon WG, Watson K, Lunt K et al. British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DPM. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum. 54, 2368-2376 (2006).
45. Dixon WG, Hyrich KL, Watson KD et al. BSRBR Control Centre Consortium, Symmons DP, BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis. 69, 522-528 (2010).
46. Galloway JB, Hyrich KL, Mercer LK et al. BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 50, 124-131 (2011).
47. Askling J, Fored CM, Brandt L et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann. Rheum. Dis. 66, 1339-1344 (2007).
48. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 52, 3403-3412 (2005).
49. Tubach F, Salmon D, Ravaud P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 60(7), 1884-1894 (2009).
50. Dixon WG, Hyrich KL, Watson KD et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis. 69(3), 522-528 (2010).
51. Atzeni F, Biasi D, Botsios C et al. Long-term anti-TNF therapy and risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison among adalimumab, etanercept and infliximab. Ann. Rheum. Dis. 70(Suppl. 3), abstract 229 (2011).
52. Strangfeld A, Listing J, Herzer P et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301, 737-744 (2009).
53. Galloway JB, Hyrich KL, Mercer LK et al. BSR Biologics Register. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 70, 1810-1814 (2011).
54. Keystone EC. Does anti-tumor necrosis factor-{alpha} therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: A review of longterm data. J. Rheumatol. 38, 1552-1562 (2011).
55. Bordas X, Martin-Sala S. Etanercept and chronic infection by HCV and HBV. Actas Dermosifiliogr. 101(Suppl. 1), 82-87 (2010).
56. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: A systematic review. Rheumatology 50(9), 1700-1711 (2011).
57. Caporali R, Bobbio-Pallavicini F, Atzeni F et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care. Res. 62(6), 749-754 (2010).
58. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 56(5), 1433-1439 (2007).
59. Askling J, Fored CM, Baecklund E et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 64, 1414-1420 (2005).
60. Askling J, Fored CM, Brandt L et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann. Rheum. Dis 64, 1421-1426 (2005).
61. Mariette X, Matucci-Cerinic M, Pavelka K et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis. Ann. Rheum. Dis. 70(11), 1895-1904 (2011).
62. Mann DL, McMurray JJ, Packer M et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomised Etanercept World-wide Evaluation (RENEWAL). Circulation 109, 1594-1602 (2004).
63. Jacobsson LT, Turesson C, Gülfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32, 1213-1218 (2005).
64. Dixon WG, Watson KD, Lunt M et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor a therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56(9), 2905-2912 (2007).
65. Lunt M, Watson KD, Dixon WG et al. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the british society for rheumatology biologics register. Arthritis Rheum. 62, 3145-3153 (2010).
66. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann. NY Acad. Sci. 1051, 559-569 (2005).
67. Atzeni F, Sarzi-Puttini P. Autoantibody production in patients treated with anti-TNF-alpha. Expert Rev. Clin. Immunol. 4, 275-280 (2008).
68. Saint Marcoux B, De Bandt M; CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: A study in 39 patients in France. Joint Bone Spine 73, 710-713 (2006).
69. Abourazzak FE, Guggenbuhl P, Perdriger A et al. Cutaneous lupus induced by etanercept in rheumatoid arthritis. Rev. Med. Interne. 29, 744-747 (2008).
70. Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: Drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann. Rheum. Dis. 68(11), 1793-1794 (2009).
71. Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium, BSR Biologics Register. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 70(5), 823-826 (2011).
72. Hazes JM, Coulie PG, Geenen V et al. Rheumatoid arthritis and pregnancy: Evolution of disease activity and pathophysiological considerations for drug use. Rheumatology 50(11), 1955-1968 (2011).
73. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315-324 (1988).
74. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964-975 (2010).
75. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta-analysis of efficacy and safety. BMC Musculoskelet. Disord. 9, 52 (2008).
76. Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: A network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 16 (2), CD008794 (2011).
77. Weinblatt M, Bathon J, Kremer JM et al. Safety and efficacy of etanercept beyond 10 years therapy in North American patients with early and long-standing rheumatoid arthritis. Arthritis Care Res. 63, 373-382 (2011).
78. Atzeni F, Sarzi-Puttini P, Gorla R, Marchesoni A, Caporali R. Switching rheumatoid arthritis treatments: An update. Autoimmun. Rev. 10(7), 397-403 (2011).
79. Soini E, Hallinen T, Puolakka K, Vihervaara V, Kauppi M. Cost-effectiveness of adalimumab, etanercept and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J. Med. Econ. doi:10.3111/13696998.2011.649327 (2011) (Epub ahead of print).
80. Gu N, Yi S, Kim TE et al. Comparative Pharmacokinetics and Tolerability of Branded Etanercept (25 mg) and Its Biosimilar (25 mg): A randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. Clin. Ther. 33(12), 2029-2037 (2011).